CLOs on the Move

MediGene

www.medigene.com

 
About MediGene: MediGene AG is a publicly quoted (Frankfurt: Prime Standard), German-American biotechnology company located in Martinsried, Germany and San Diego, USA. MediGene is the first German biotech company with a drug on the market. The company
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.medigene.com
  • 10660 Scripps Ranch Blvd Ste 200
    San Diego, CA USA 92131
  • Phone: 858.586.2240

Executives

Name Title Contact Details

Similar Companies

Roche NimbleGen

Roche NimbleGen, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Metabiota

Metabiota is the pioneer in comprehensive risk analytics that improve the world`s resilience to epidemics. Built on a strong foundation of epidemiology and international field science, including a worldwide network of on-the-ground experts, Metabiota delivers actionable, data-driven insights that help countries, governments and corporations manage and mitigate infectious diseases. With a strategic global presence and sustained partnerships, Metabiota`s agile approach is helping the world track and transfer the risk associated with epidemic threats.

Inhibitex

Inhibitex, Inc. is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Carol Cole Company

Carol Cole Company is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Minaris Advanced Therapies

Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized LYFGENIA, a gene therapy for sickle cell disease. With a focus on collaboration, Minaris serves over 180 biotech and pharmaceutical clients, providing tailored solutions for their specific needs in regenerative medicine. Its facilities include expanded cleanroom capacity and analytical labs to support large-scale production.